Has Paul Adams, MD received payments from drug or device companies?

Yes. Drug and device makers reported $76,406 in general payments to Paul Adams, MD across 305 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Adams, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Adams, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Adams, MD

Hematology & Oncology · Flint, MINPI 1811952591

Payments from drug & device makers

$76,406in general payments, 2019–2025

Across 305 payments — averaging $250.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bristol Myers Squibb$63K
E.r. Squibb & Sons, L.L.C.$7K
Novartis$819
Genentech USA, Inc.$481
Johnson & Johnson$360
AstraZeneca$358
plus $4K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bristol Myers Squibb	24	$63,382
E.r. Squibb & Sons, L.L.C.	13	$7,333
Novartis	50	$819
Genentech USA, Inc.	23	$481
Johnson & Johnson(2 entities)	20	$360
AstraZeneca(2 entities)	14	$358
Pharmacyclics LLC, An Abbvie Company	5	$197
Pfizer	12	$190
Merck	5	$181
Sanofi	7	$178
EMD Serono, Inc.	8	$166
AbbVie	3	$157
Gilead(2 entities)	4	$152
GSK	8	$144
Astellas Pharma US Inc	5	$139
Deciphera Pharmaceuticals Inc.	7	$122
Genmab U.S., Inc.	4	$101
Amgen	5	$99
Incyte Corporation	6	$98
Ipsen Biopharmaceuticals, Inc	5	$94
Beigene USA, Inc.	4	$90
Dendreon Pharmaceuticals LLC	3	$78
AVEO Pharmaceuticals, Inc.	2	$71
Foundation Medicine, Inc.	2	$70
Eisai Inc.	3	$69
Acrotech Biopharma Inc.	4	$68
Geron Corporation	2	$63
Daiichi Sankyo Inc.	3	$59
Seagen Inc.	3	$50
Takeda Pharmaceuticals U.S.A., Inc.	2	$50
Lilly USA, LLC	3	$49
Tersera Therapeutics LLC	2	$47
Legend Biotech USA Inc.	2	$47
Jazz Pharmaceuticals Inc.	2	$47
Apellis Pharmaceuticals, Inc.	2	$46
Beone Medicines USA, Inc.	2	$41
Kyowa Kirin, Inc.	2	$39
Pharmaessentia USA Corporation	2	$39
Rigel Pharmaceuticals, Inc.	2	$38
Bayer	2	$37
Karyopharm Therapeutics Inc.	2	$37
Servier Pharmaceuticals LLC	2	$36
G1 Therapeutics, Inc.	2	$35
Coherus Oncology, Inc.	1	$33
Adaptive Biotechnologies Corporation	1	$33
Octapharma USA, Inc.	1	$32
Springworks Therapeutics, Inc.	1	$24
Tolmar Pharmaceuticals, Inc.	1	$23
Mirati Therapeutics, Inc.	1	$22
Regeneron Healthcare Solutions, Inc.	1	$22
Myovant Sciences Inc.	1	$21
Menarini Silicon Biosystems, Inc.	1	$21
Blueprint Medicines Corporation	1	$20
Verity Pharmaceuticals Inc.	1	$20
Spectrum Pharmaceuticals Inc.	1	$19
Azurity Pharmaceuticals, Inc.	1	$19
Stemline Therapeutics Inc.	1	$18
Pharmacosmos Therapeutics Inc.	1	$17
Myriad Genetic Laboratories, Inc.	1	$17
AMAG Pharmaceuticals, Inc.	1	$17

How this compares

$76,406 in reported general payments places this provider in the 80th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan →

Medicare billing

Part B allowed, 2024

$1,194,873

Medicare patients

449

Services billed

73,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Flint

Madan AroraFlint$84K
Rizwan DanishFlint$49K
Sreenivasa ChandanaGrand Rapids$19.1M
Nehal LakhaniGrand Rapids$15M
Hirva MamdaniDetroit$9.5M
Jeffrey ZonderDetroit$8.2M
Assuntina SaccoAnn Arbor$8.1M
Abhinav DeolDetroit$4.5M
Harsh ShahDetroit$2.6M
Igor RybkinDetroit$2.4M

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →